{"id":"ensifentrine-dose-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CFTR and ENaC, ensifentrine increases the chloride ion conductance across epithelial membranes, leading to improved lung function in patients with cystic fibrosis. This dual inhibition also reduces sodium absorption, further contributing to the therapeutic effect.","oneSentence":"Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:02.448Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT07016412","phase":"PHASE2","title":"A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD","status":"RECRUITING","sponsor":"Verona Pharma plc","startDate":"2025-07-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":480},{"nctId":"NCT07132983","phase":"PHASE2","title":"A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2025-10-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33},{"nctId":"NCT04535986","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2020-09-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":763},{"nctId":"NCT04542057","phase":"PHASE3","title":"A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2020-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":790},{"nctId":"NCT05758428","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Nuance Pharma (shanghai) Co., Ltd","startDate":"2023-03-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":28},{"nctId":"NCT04027439","phase":"PHASE2","title":"Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2018-12-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":37},{"nctId":"NCT04527471","phase":"PHASE2","title":"Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Verona Pharma Inc","startDate":"2020-09-04","conditions":"Coronavirus Infection, Covid-19, SARS-CoV-2","enrollment":45},{"nctId":"NCT04091360","phase":"PHASE2","title":"A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2019-04-29","conditions":"COPD","enrollment":40},{"nctId":"NCT03937479","phase":"PHASE2","title":"Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2019-05-01","conditions":"COPD","enrollment":416},{"nctId":"NCT02427165","phase":"PHASE2","title":"Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2015-04","conditions":"Asthma","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ensifentrine Dose 1","genericName":"Ensifentrine Dose 1","companyName":"Verona Pharma Inc","companyId":"verona-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC). Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}